Skip to main content
Erschienen in: International Journal of Hematology 3/2012

01.03.2012 | Progress in Hematology

Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes

verfasst von: Hideki Tsushima, Masako Iwanaga, Yasushi Miyazaki

Erschienen in: International Journal of Hematology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Leukemia was the first malignancy linked to radiation exposure in atomic bomb survivors. Clear evidence of the dose-dependent excess risk of three major types of leukemia (acute lymphocytic leukemia, acute myeloid leukemia [AML], and chronic myeloid leukemia) was found, especially in people exposed at young ages. Such leukemia risks were at their highest in the late 1950s, and declined gradually thereafter over the past 50 years. Findings from recent risk analyses, however, suggest the persistence of AML risk even after 1990, and evidence of increased risk of myelodysplastic syndromes (MDS) due to atomic bomb radiation has recently been shown. High-risk MDS and forms involving complex chromosomal aberrations were found to be much more frequent in people exposed to higher radiation doses. These lines of epidemiological evidence suggest that the risk of radiation-induced hematological malignancies has persisted for six decades since the initial exposure.
Literatur
1.
Zurück zum Zitat Fo1ley JH, Borges W, Yamasaki T. Incidence of leukemia in the atomic bomb survivors of Hiroshima and Nagasaki, Japan. Am J Med. 1952;13:311–21. Fo1ley JH, Borges W, Yamasaki T. Incidence of leukemia in the atomic bomb survivors of Hiroshima and Nagasaki, Japan. Am J Med. 1952;13:311–21.
2.
Zurück zum Zitat Ishimaru T, Hoshino T, Ichimaru M, Okada H, Tomiyasu T. Leukemia in atomic bomb survivors, Hiroshima and Nagasaki, 1 (October), pp. 1950–30, September 1966. Radiat Res. 1971;45(1):216–33.PubMedCrossRef Ishimaru T, Hoshino T, Ichimaru M, Okada H, Tomiyasu T. Leukemia in atomic bomb survivors, Hiroshima and Nagasaki, 1 (October), pp. 1950–30, September 1966. Radiat Res. 1971;45(1):216–33.PubMedCrossRef
3.
Zurück zum Zitat Ichimaru M, Ishimaru T, Belsky JH. Incidence of leukemia in Atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950–71. Radiation dose, years after exposure, age at exposure, and type of leukemia. J Radiat Res. 1978;19:262–82.PubMedCrossRef Ichimaru M, Ishimaru T, Belsky JH. Incidence of leukemia in Atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950–71. Radiation dose, years after exposure, age at exposure, and type of leukemia. J Radiat Res. 1978;19:262–82.PubMedCrossRef
4.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.PubMedCrossRef Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.PubMedCrossRef
5.
Zurück zum Zitat Matsuo T, Tomonaga M, Bennett JM, Kuriyama K, Imanaka F, Kuramoto A, et al. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol. 1988;18:91–6.PubMed Matsuo T, Tomonaga M, Bennett JM, Kuriyama K, Imanaka F, Kuramoto A, et al. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol. 1988;18:91–6.PubMed
6.
Zurück zum Zitat Tomonaga M, Matsuo T, Carter RL, et al. Differential effects of atomic bomb irradiation in inducing major leukemia types: analyses of open-city cases including the Life Span Study cohort based upon update diagnostic systems and the dosimetry system 1986 (DS86). RERF TR 9-91. 1993. Tomonaga M, Matsuo T, Carter RL, et al. Differential effects of atomic bomb irradiation in inducing major leukemia types: analyses of open-city cases including the Life Span Study cohort based upon update diagnostic systems and the dosimetry system 1986 (DS86). RERF TR 9-91. 1993.
7.
Zurück zum Zitat Kamada N, Tanaka K, Oguma N, Mabuchi K. Cytogenetic and molecular changes in leukemia among atomic bomb survivors. J Radiat Res (Tokyo). 1991;32(Suppl 2):257–65.CrossRef Kamada N, Tanaka K, Oguma N, Mabuchi K. Cytogenetic and molecular changes in leukemia among atomic bomb survivors. J Radiat Res (Tokyo). 1991;32(Suppl 2):257–65.CrossRef
8.
Zurück zum Zitat Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic-bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137:S68–97.PubMedCrossRef Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic-bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res. 1994;137:S68–97.PubMedCrossRef
9.
Zurück zum Zitat Richardson D, Sugiyama H, Nishi N, Sakata R, Shimizu Y, Grant EJ, Soda M, Hsu WL, Suyama A, Kodama K, Kasagi F. Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950–2000. Radiat Res. 2009;172:368–82.PubMedCrossRef Richardson D, Sugiyama H, Nishi N, Sakata R, Shimizu Y, Grant EJ, Soda M, Hsu WL, Suyama A, Kodama K, Kasagi F. Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950–2000. Radiat Res. 2009;172:368–82.PubMedCrossRef
10.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.PubMed Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.PubMed
11.
Zurück zum Zitat Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, Amenomori T, Yamamura M, Yoshida Y, Koba T, Miyazaki Y, Matsuo T, Preston DL, Suyama A, Kodama K, Tomonaga M. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29:428–34.PubMedCrossRef Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, Amenomori T, Yamamura M, Yoshida Y, Koba T, Miyazaki Y, Matsuo T, Preston DL, Suyama A, Kodama K, Tomonaga M. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29:428–34.PubMedCrossRef
Metadaten
Titel
Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes
verfasst von
Hideki Tsushima
Masako Iwanaga
Yasushi Miyazaki
Publikationsdatum
01.03.2012
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2012
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-012-1002-4

Weitere Artikel der Ausgabe 3/2012

International Journal of Hematology 3/2012 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.